Amanta Healthcare Ltd

Amanta Healthcare Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, as per SEBI regulations. The report, issued by CRISIL Ratings Limited, details the utilization of funds raised through the company's Initial Public Offer (IPO). The IPO, which occurred from September 1-3, 2025, raised gross proceeds of ₹12,600.00 lakhs. After deducting issue expenses of ₹2,284.81 lakhs, the net proceeds amounted to ₹10,315.19 lakhs. The report confirms no deviation from the objects of the issue. The net proceeds were revised from an earlier estimate due to higher-than-actual issue expenses, with the difference adjusted against general corporate purposes.

Amanta Healthcare Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, approved the unaudited financial results for the quarter ended June 30, 2026. The Board also approved the Limited Review Report from the auditors with an unmodified opinion. Additionally, the company approved the Board's Report for the financial year ended March 31, 2026, and the notice for the 31st Annual General Meeting scheduled for September 16, 2026. The appointment of Mr. Kashyap R. Mehta as Scrutinizer for the AGM's e-voting process was also approved, along with the dissolution of the IPO Committee.

Amanta Healthcare Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the Board's Report for the financial year ended March 31, 2026, and the notice for the 31st Annual General Meeting scheduled for September 16, 2026. The company also approved the dissolution of its IPO Committee. The limited review report from auditors Price Waterhouse Chartered Accountants LLP was also approved, with an unmodified opinion.

Amanta Healthcare Limited announced its unaudited financial results for the quarter ended June 30, 2026. Revenue for Q1FY27 stood at ₹68.8 crore, a 5.4% year-on-year growth, attributed to an improved product mix and better price realizations. EBITDA was ₹15.2 crore, with margins at 22%, a decrease from 24% in Q1FY26 due to increased raw material, employee, and operating costs. Profit After Tax (PAT) declined by 5.6% YoY to ₹3.3 crore, impacted by higher finance costs from a new Solar Term Loan. The company is progressing with capacity expansion, expecting the Steriport plant to be commissioned by Q2FY27 and SVP expansion by Q4FY27, alongside a solar power project to enhance manufacturing capacity and cost efficiency.

Amanta Healthcare Ltd has submitted its statement of deviation or variation in the utilization of funds raised through its Initial Public Offer (IPO). For the quarter ended June 30, 2026, the company confirms there has been no deviation or variation in the use of proceeds. The funds were raised on September 09, 2025, amounting to ₹126 crore. The statement, reviewed by the Audit Committee, indicates that all allocated funds were utilized as per the original plan, with minor adjustments noted for issue expenses and general corporate purposes due to GST payments, which were duly accounted for and affirmed by the monitoring agency.

Amanta Healthcare Ltd announced the inclusion of Mr. Nilesh Punjabi as Senior Management Personnel (SMP), effective August 5, 2026. This decision was approved by the Board of Directors, following a recommendation from the Nomination and Remuneration Committee. Mr. Punjabi, Assistant Vice President (HR & Admin), brings over 20 years of HR experience from companies like United Breweries Ltd, Hettich India, Zydus Cadila, Kohler India, and 3M India Ltd. He holds an MBA in Human Resource Development and a Post Graduate degree in HRM from XLRI Jamshedpur. This appointment is in line with SEBI (LODR) Regulations, 2015.

Amanta Healthcare Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item for this meeting is to consider and approve the unaudited financial results for the first quarter ended June 30, 2026. Additionally, the company has informed that the trading window, which was closed from July 1, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, will reopen on August 8, 2026.

Bhavesh Girishbhai Patel, a promoter of Amanta Healthcare Limited, has acquired 1,000 equity shares of the company through an off-market inter-se transfer from Kirit Desai, a member of the promoter group. The transaction, which occurred on June 30, 2026, involved a consideration of Rs. 160 per share. This transfer does not alter the overall promoter holding percentage as it is an internal transfer within the promoter group. The acquisition represents 0.002% of the total voting rights. The total equity share capital of the company remains unchanged.

Amanta Healthcare Ltd has filed disclosures regarding an off-market transfer of equity shares between its promoter, Shri Bhavesh Girishbhai Patel, and a member of the promoter group, Shri Kirit Ambalal Desai. The transfer involved 63,31,179 shares, with a purchase of 63,32,179 shares, indicating a net change of 100 shares. This transaction, dated June 30, 2026, is classified as an inter-se transfer within the promoter group and is reported under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. No derivatives trading was reported by the involved parties.

Amanta Healthcare Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut for insiders, connected persons, designated persons, and their immediate relatives from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is standard practice to prevent potential insider trading during sensitive financial reporting periods.